Literature DB >> 22370970

Impaired cell functions of hepatocytes incubated with plasma of septic patients.

Martin Sauer1, Cristof Haubner, Thomas Mencke, Gabriele Nöldge-Schomburg, Steffen Mitzner, Jens Altrichter, Jan Stange.   

Abstract

OBJECTIVE AND
DESIGN: The development of liver failure is a major problem in septic patients. In this prospective clinical experimental study the hepatotoxicity of plasma from septic and non-septic patients was tested. METHODS AND
SUBJECTS: The basic test components consist of human liver cells (HepG2/C3A) used in a standardized microtiter plate assay. After incubation with patient's plasma viability of cells (XTT-test), the cytochrome 1A2 activity and synthesis of micro albumin were measured. Subjects (28) enrolled comprise the septic shock group (SSG, n=10), the non-septic group (NSG, n=5) and the healthy volunteers group (HVG, n=13).
RESULTS: The 28-day mortality was 30% in the SSG. The APACHE II-, SOFA-, and SAPS-scores and the values of bilirubin and prothrombin time as INR were significantly higher in the SSG than in the NSG. The cytochrome 1A2 activity and the release of albumin were significantly reduced in HepG2/C3A cells incubated with plasma of the SSG (p<0.05). The cytochrome 1A2 activities were higher in survivors compared to non-survivors at the time point 0 and were increasing in survivors and decreasing in non-survivors within 54 h in the SSG. In the SSG there was a significant decrease in IL-10 and IL-8 between inclusion and 54 h. Values of IL-6, TNF alpha and IL-10 were significantly lower in the NSG compared with the values of the SSG at inclusion and after 54 h.
CONCLUSION: The plasma of patients with septic shock impaired cellular functions of HepG2/C3A cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370970     DOI: 10.1007/s00011-012-0451-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  43 in total

Review 1.  Hepatic hemodynamics and cell functions in human and experimental sepsis.

Authors:  C M Pastor; P M Suter
Journal:  Anesth Analg       Date:  1999-08       Impact factor: 5.108

Review 2.  Sepsis and cholestasis.

Authors:  Richard H Moseley
Journal:  Clin Liver Dis       Date:  2004-02       Impact factor: 6.126

3.  Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure.

Authors:  A J Ellis; R D Hughes; J A Wendon; J Dunne; P G Langley; J H Kelly; G T Gislason; N L Sussman; R Williams
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

4.  Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2.

Authors:  J H Kelly; G J Darlington
Journal:  In Vitro Cell Dev Biol       Date:  1989-02

Review 5.  Current insights in sepsis: from pathogenesis to new treatment targets.

Authors:  W Joost Wiersinga
Journal:  Curr Opin Crit Care       Date:  2011-10       Impact factor: 3.687

6.  The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM.

Authors:  R Moreno; J L Vincent; R Matos; A Mendonça; F Cantraine; L Thijs; J Takala; C Sprung; M Antonelli; H Bruining; S Willatts
Journal:  Intensive Care Med       Date:  1999-07       Impact factor: 17.440

7.  Mixed function oxidase and UDP-glucuronyltransferase activities in the human Hep G2 hepatoma cell line.

Authors:  M H Grant; S J Duthie; A G Gray; M D Burke
Journal:  Biochem Pharmacol       Date:  1988-11-01       Impact factor: 5.858

8.  Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients.

Authors:  Andreas Hillenbrand; Uwe Knippschild; Manfred Weiss; Hubert Schrezenmeier; Doris Henne-Bruns; Markus Huber-Lang; Anna M Wolf
Journal:  BMC Surg       Date:  2010-09-09       Impact factor: 2.102

9.  Expression of cathepsin B and aryl hydrocarbon hydroxylase activities, and of apolipoprotein B in human hepatoma cells maintained long-term in a serum-free medium.

Authors:  M Dufresne; D Jane; A Theriault; K Adeli
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

10.  Hepatic dysfunction increases length of stay and risk of death after injury.

Authors:  Brian G Harbrecht; Mazen S Zenati; Howard R Doyle; John McMichael; Ricard N Townsend; Keith D Clancy; Andrew B Peitzman
Journal:  J Trauma       Date:  2002-09
View more
  5 in total

1.  Bioartificial Therapy of Sepsis: Changes of Norepinephrine-Dosage in Patients and Influence on Dynamic and Cell Based Liver Tests during Extracorporeal Treatments.

Authors:  Martin Sauer; Jens Altrichter; Cristof Haubner; Annette Pertschy; Thomas Wild; Fanny Doß; Thomas Mencke; Maren Thomsen; Johannes Ehler; Jörg Henschel; Sandra Doß; Stephanie Koch; Georg Richter; Gabriele Nöldge-Schomburg; Steffen R Mitzner
Journal:  Biomed Res Int       Date:  2016-06-28       Impact factor: 3.411

2.  Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results.

Authors:  Sandra Doß; Heike Potschka; Fanny Doß; Steffen Mitzner; Martin Sauer
Journal:  Biomed Res Int       Date:  2017-04-04       Impact factor: 3.411

3.  Procalcitonin Impairs Liver Cell Viability and Function In Vitro: A Potential New Mechanism of Liver Dysfunction and Failure during Sepsis?

Authors:  Martin Sauer; Sandra Doß; Johannes Ehler; Thomas Mencke; Nana-Maria Wagner
Journal:  Biomed Res Int       Date:  2017-02-01       Impact factor: 3.411

4.  Impaired Cell Viability and Functionality of Hepatocytes After Incubation With Septic Plasma-Results of a Second Prospective Biosensor Study.

Authors:  Martin Sauer; Cristof Haubner; Georg Richter; Johannes Ehler; Thomas Mencke; Steffen Mitzner; Stefan Margraf; Jens Altrichter; Sandra Doß; Gabriele Nöldge-Schomburg
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

5.  Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice.

Authors:  Martina Sombetzki; Nicole Koslowski; Sandra Doss; Micha Loebermann; Michael Trauner; Emil C Reisinger; Martin Sauer
Journal:  Biomed Res Int       Date:  2016-06-08       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.